Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 30, 2023, titled "Strides reports Strong Q2FY24 Performance Revenues at ₹ 10,264m and EBITDA at ₹ 1,801m".
Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 30, 2023, titled "Strides reports Strong Q2FY24 Performance Revenues at ₹ 10,264m and EBITDA at ₹ 1,801m".